ESWL

Global Lithotripsy Devices Industry Worth $1.78B by 2026 - Discover the Leading Products, Services, Developments, and Competitors - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 23, 2022
Surgery, Health, Medical Devices, Risk, Urology, Government, Awareness, Ureter, COVID-19, Dornier, ESWL, Competitive landscape, US, Woman, Olympus Corporation, Chronic kidney disease, National Kidney Foundation, TMS, Incidence, Lithotripsy, Anesthesia, European Association of Urology, Growth, Man, MDR, IVL, Adoption, Person, Boston Scientific, CAGR, CT, Kidney, Human services, Population, Efficiency, EMS, Prevalence, EDAP, USD, Patient, Fluoroscopy, Physician, Percussion section, Bleeding, ESRD, Coronary artery disease, Ageing, Acquisition, Medical device regulation, FDA, Public employment services in the European Union, Plaque, Technology, Rock, Shock, Certification, Medical imaging, Pharmaceutical industry, Agriculture, Medical device

Owing to the occurrence of stones in various parts of the body, the Lithotripsy Devices market will rise significantly.

Key Points: 
  • Owing to the occurrence of stones in various parts of the body, the Lithotripsy Devices market will rise significantly.
  • Thus, the burgeoning cases of urolithiasis will contribute to the Global Lithotripsy Devices Market growth.
  • Such technological advancement in the field of Lithotripsy Devices is likely to boost the Global Lithotripsy Devices Market during the forecast period.
  • In the by-type segment of the Lithotripsy Devices market, the Extracorporeal Shock Wave Lithotripsy Devices (ESWL) market segment will hold a significant share in the Global Lithotripsy Devices market.

EDAP Issues Letter to Shareholders

Retrieved on: 
Tuesday, February 1, 2022
EDAP, Growth, Prostate cancer, Safety, Patient, Urology, Hospital, Pathology, Pancreatic cancer, Cancer, Physician, Focal, Prisma Health, Google Images, Technology, Adoption, Work, COVID-19, Marketing, U.S. Securities and Exchange Commission, Annual report, Company, Laser, Duke University, Letter, ESWL, Security (finance), University of California, San Diego, TMS, Risk, Robotics, HIFU, Nasdaq, Pharmaceutical industry, Medical imaging, Brigham

LYON, France, February 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:

Key Points: 
  • LYON, France, February 1, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today issued the following letter to shareholders:
    As we closed the book on 2021, I am once again pleased by the success of the entire EDAP team in navigating through the ongoing pandemic that has made virtually all business operations far more challenging.
  • Following our strong fourth quarter momentum and with a solid cash position, EDAP enters 2022 with high expectations.
  • I would like to thank the entire EDAP team for their tireless work and dedication to get us to this point and you, our shareholders, for your continued support.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

Global Ultrasound Device Market (2021 to 2028) - Size, Share & Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Friday, January 21, 2022
Medical Devices, Health, CAGR, Technology, HIFU, ESWL, GE Healthcare, Adoption, Degenerative disease, Health, Artery, Tissue, Extracorporeal shockwave therapy, Asia-Pacific, Diagnosis, Artificial intelligence, Cancer, Neoplasm, Prevalence, Conditional sentence, Medical imaging, Ultrasound

An increase in the adoption of ultrasound devices for diagnosis and treatment is driving the market.

Key Points: 
  • An increase in the adoption of ultrasound devices for diagnosis and treatment is driving the market.
  • In addition, a rise in the adoption of minimally invasive surgeries, coupled with technological advancements, is expected to boost market growth.
  • Hand-held ultrasound devices have made the technology more accessible for use in limited-resource communities around the world.
  • Asia Pacific is anticipated to expand at the fastest CAGR over the forecast period owing to the increased demand for better imaging devices

EDAP Announces Publication of Positive Pre-clinical Results Using Intraoperative HIFU Ablation of the Pancreas in the Journal Cancers

Retrieved on: 
Thursday, January 13, 2022
Survival, Pancreas, Google Images, HIFU, Patient, First Step, Focal, EDAP, ESWL, Pathology, Clinical, COVID-19, Laser, Safety, Cancer, Risk, LAPA, Prostate cancer, Pancreatic cancer, U.S. Securities and Exchange Commission, TMS, Nasdaq, Tissue, Company, Perioperative, Doppler effect, Security (finance), Annual report, Pharmaceutical industry, Medical imaging

LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announces the publication of positive pre-clinical results using intraoperative high intensity focused ultrasound (HIFU) ablation of the pancreas in the peer-reviewed journal Cancers.

Key Points: 
  • LYON, France, January 13, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announces the publication of positive pre-clinical results using intraoperative high intensity focused ultrasound (HIFU) ablation of the pancreas in the peer-reviewed journal Cancers.
  • The paper, entitled, Intraoperative HIFU Ablation of the Pancreas Using a Toroidal Transducer in a Porcine Model.
  • Regardless of treatment, the overall 5-year survival rate for patients with locally advanced pancreatic adenocarcinoma (LAPA) is less than 5%.
  • The possibility of treating the pancreas using HIFU holds great promise for the treatment of locally advanced pancreatic cancers.

EDAP Provides Corporate Update on US Focal One Installation Growth

Retrieved on: 
Wednesday, January 5, 2022
Prisma Health, COVID-19, Laser, University, TMS, University of California, San Francisco, Growth, University of California, Irvine, HIFU, UC, ESWL, Prostate cancer, U.S. Securities and Exchange Commission, Annual report, Duke University, Security (finance), Risk, UCSD, CEO, Focal, Sale, Adoption, Nasdaq, San Diego, EDAP, Optimism, San Francisco, Google Images, Pharmaceutical industry, Medical imaging, Company, Brigham

LYON, France, January 5, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today provided an update on recent Focal One placements and the initiation of treatments at select new customer sites in the US.

Key Points: 
  • During the companys third quarter 2021 conference call in November, EDAP announced that it had sold a Focal One device to the University of California at San Diego (UCSD) during the fourth quarter.
  • The sale to UCSD is now the third Focal One placement into the prestigious UC healthcare system, following previously announced sales to UC San Francisco and UC Irvine.
  • In addition, the company is today announcing that additional Focal One installations have occurred during the fourth quarter to five prestigious academic and integrated health network reference centers.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

EDAP to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Retrieved on: 
Monday, November 29, 2021
Prostate cancer, Security (finance), EDAP, Risk, Conference, Annual report, Company, Focal, Google Images, Laser, ESWL, Investor, U.S. Securities and Exchange Commission, COVID-19, HIFU, Nasdaq, Piper Sandler Companies, TMS, Medical imaging

LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which is being held November 29 - December 2.

Key Points: 
  • LYON, France, November 29, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic energy-based therapies, today announced that the company will participate in a fireside chat and host investor 1x1 meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference, which is being held November 29 - December 2.
  • EDAP will be participating in investor meetings on Tuesday, November 30.
  • A video replay of the fireside chat will be available on the Investors section of the EDAP website following the conclusion of the event.
  • A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

EDAP TMS SA to Announce Third Quarter 2021 Financial Results on Wednesday, November 17, 2021

Retrieved on: 
Wednesday, November 10, 2021
HIFU, EDAP, TMS, ESWL, Focal, Laser, Prostate cancer, Company, Google Images, Medical imaging

A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.

Key Points: 
  • A recognized leader in the global therapeutic ultrasound market,EDAP TMSdevelops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • EDAP TMS also produces and distributes other medical equipment including the Sonolith i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL).
  • For more information on the Company, please visit http://www.edap-tms.com , and us.hifu-prostate.com .

EDAP Announces University of Washington Medicine to Launch Focal One® Robotic HIFU Program

Retrieved on: 
Tuesday, September 28, 2021
Academic health science centre, U.S. News & World Report, Man, MRI, Laser, Risk, Health, Annual report, ESWL, Security (finance), Focal, News, U.S. Securities and Exchange Commission, Patient, University of Washington School of Medicine, Urology, Physician, Association, TMS, Seattle Cancer Care Alliance, Ownership, Prostate cancer, Fred Hutchinson Cancer Research Center, Association of American Medical Colleges, Company, University, Prostate, Google Images, HIFU, 3D, COVID-19, Technology, EDAP, Contract, Nasdaq, Airlift Northwest, Medical imaging, Pharmaceutical industry

LYON, France, September 28, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that University of Washington Medicine has acquired the company’s Focal One® high intensity focused ultrasound (HIFU) technology for the precise ablation of prostate tissue. UW Medicine will implement the focal therapy program with Focal One at its UW Medical Center location.

Key Points: 
  • UW Medicine will implement the focal therapy program with Focal One at its UW Medical Center location.
  • We are pleased that UW Medicine has chosen to offer Focal One Robotic HIFU to their patients, said Marc Oczachowski, Chairman and Chief Executive Officer of EDAP.
  • Focal One is the most advanced system for the precise ablation of prostate tissue using HIFU.
  • The University of Washington School of Medicine, part of the system, leads the internationally recognized, community-based WWAMI Program, which servesWashington, Wyoming, Alaska, Montana and Idaho.

EDAP Announces Presentation of Multiple Abstracts Favorably Comparing HIFU to Surgery at the American Urological Association 2021 Annual Meeting

Retrieved on: 
Tuesday, September 14, 2021
Gold, Prostatectomy, U.S. Securities and Exchange Commission, Security (finance), EDAP, Curative, American Urological Association, Technology, TMS, Randomized controlled trial, Patient, Company, ESWL, Nasdaq, Local, Prostate cancer, Google Images, Annual report, Survival, ISUP, Growth, COVID-19, Annual general meeting, AUA, HIFU, Risk, Focal, Laser, Medical imaging

LYON, France, September 14, 2021 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that the company’s Focal One and ExactVu technologies were featured in several poster presentations at the American Urological Association (AUA) 2021 Annual Meeting, which was held virtually from September 10-13. EDAP was a Gold sponsor of the event.

Key Points: 
  • The data suggest that at one-year post treatment, Focal One achieved good oncological efficacy while preserving erectile function and urinary continence better than radical prostatectomy.
  • The intermediate results presented show a salvage-treatment-free survival rate significantly higher in the HIFU arm (97.5%) compared to the radical prostatectomy arm (90.3%).
  • In terms of both efficacy and long-term survival, Focal One offers patients a superior treatment option without the debilitating side effects associated with surgery.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

EDAP to Participate at Upcoming Investor Conferences

Retrieved on: 
Tuesday, September 7, 2021

To receive additional information, request an invitation or to schedule a one-on-one meeting, please visit ( https://www.lakestreetcapitalmarkets.com/big5conference ) or contact your Lake Street representative.

Key Points: 
  • To receive additional information, request an invitation or to schedule a one-on-one meeting, please visit ( https://www.lakestreetcapitalmarkets.com/big5conference ) or contact your Lake Street representative.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.
  • Lake Street will host its fifth annual BIG (Best Ideas Growth) institutional investor conference showcasing many interesting, dynamic public growth companies.